Insider · CIK 0001696493

Lee June

Reports to the SEC for 4 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001696493

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-28	TNYATenaya Therapeutics, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+120K sh	—	—	120,000
2026-01-10	ELDNEledon Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,430 sh	—	—	3,430
2026-01-10	ELDNEledon Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,430 sh	—	—	0
2025-05-29	TNYATenaya Therapeutics, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+107K sh	—	—	107,400
2025-01-10	ELDNEledon Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+30.9K sh	—	—	30,870
2025-01-10	ELDNEledon Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director	AAward	+3,430 sh	—	—	3,430
2024-10-18	TNYATenaya Therapeutics, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+34K sh	—	—	34,000
2023-06-09	TNYATenaya Therapeutics, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+29.5K sh	—	—	29,532
2023-05-01	ELDNEledon Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+150K sh	—	—	150,437
2023-02-24	CinCor Pharma, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−48K sh	—	—	0
2023-02-01	ELDNEledon Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2022-06-10	TNYATenaya Therapeutics, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+39.7K sh	—	—	39,727
2022-02-01	ELDNEledon Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2022-01-06	CinCor Pharma, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+48K sh	—	—	47,954
2021-11-19	TNYATenaya Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.9K sh	—	—	18,937
2019-09-23	MyoKardia, Inc.M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	+12.6K sh	$11.95	+$151K	17,204
2019-09-23	MyoKardia, Inc.S Sale	EVP, Chief Development Officer	SSale	−3,929 sh	$58.33	−$229K	13,275
2019-09-23	MyoKardia, Inc.S Sale	EVP, Chief Development Officer	SSale	−4,161 sh	$58.97	−$245K	9,114
2019-09-23	MyoKardia, Inc.S Sale	EVP, Chief Development Officer	SSale	−800 sh	$59.95	−$48K	8,314
2019-09-23	MyoKardia, Inc.S Sale	EVP, Chief Development Officer	SSale	−4,161 sh	$61.09	−$254K	4,153
2019-09-23	MyoKardia, Inc.Stock Option (Right to Buy)M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	−12.6K sh	—	—	115,617
2019-09-19	MyoKardia, Inc.M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	+5,435 sh	$11.95	+$64.9K	10,014
2019-09-19	MyoKardia, Inc.S Sale	EVP, Chief Development Officer	SSale	−5,435 sh	$57.08	−$310K	4,579
2019-09-19	MyoKardia, Inc.Stock Option (Right to Buy)M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	−5,435 sh	—	—	128,242
2019-08-09	MyoKardia, Inc.M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	+4,565 sh	$11.95	+$54.6K	9,144
2019-08-09	MyoKardia, Inc.S Sale	EVP, Chief Development Officer	SSale	−4,565 sh	$57.00	−$260K	4,579
2019-08-09	MyoKardia, Inc.Stock Option (Right to Buy)M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	−4,565 sh	—	—	133,677
2019-04-30	MyoKardia, Inc.A Award	EVP, Chief Development Officer	AAward	+401 sh	$40.78	+$16.4K	4,579
2019-03-14	MyoKardia, Inc.M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	+1,758 sh	$11.95	+$21K	4,178
2019-03-14	MyoKardia, Inc.Stock Option (Right to Buy)M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	−1,758 sh	—	—	138,242
2019-02-25	MyoKardia, Inc.M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	+3,000 sh	$11.95	+$35.9K	22,157
2019-02-25	MyoKardia, Inc.Stock Option (Right to Buy)M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	−3,000 sh	—	—	3,250
2019-02-08	MyoKardia, Inc.Stock Option (Right to Buy)A Award	EVP, Chief Development Officer	AAward	+65K sh	—	—	65,000
2019-02-08	MyoKardia, Inc.Restricted Stock UnitsA Award	EVP, Chief Development Officer	AAward	+22.6K sh	—	—	22,600
2019-01-07	MyoKardia, Inc.F Tax Payment	EVP, Chief Development Officer	FTax Payment	−1,100 sh	$44.06	−$48.5K	2,420
2019-01-01	MyoKardia, Inc.M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	+2,750 sh	—	—	3,520
2019-01-01	MyoKardia, Inc.Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	−2,750 sh	—	—	8,250
2018-12-03	MyoKardia, Inc.M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	+5,000 sh	$11.95	+$59.8K	5,770
2018-12-03	MyoKardia, Inc.S Sale	EVP, Chief Development Officer	SSale	+2,800 sh	$60.08	+$168K	2,970
2018-12-03	MyoKardia, Inc.S Sale	EVP, Chief Development Officer	SSale	+1,200 sh	$61.07	+$73.3K	1,770
2018-12-03	MyoKardia, Inc.S Sale	EVP, Chief Development Officer	SSale	+800 sh	$62.26	+$49.8K	970
2018-12-03	MyoKardia, Inc.S Sale	EVP, Chief Development Officer	SSale	+200 sh	$63.76	+$12.8K	770
2018-12-03	MyoKardia, Inc.Stock Option (Right to Buy)M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	−5,000 sh	—	—	140,000
2018-12-03	MyoKardia, Inc.M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	+364 sh	$11.95	+$4,349.8	19,157
2018-12-03	MyoKardia, Inc.Stock Option (Right to Buy)M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	−364 sh	—	—	100,613
2018-11-06	MyoKardia, Inc.M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	+364 sh	$11.95	+$4,349.8	18,793
2018-11-06	MyoKardia, Inc.Stock Option (Right to Buy)M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	−364 sh	—	—	100,977
2018-10-31	MyoKardia, Inc.A Award	EVP, Chief Development Officer	AAward	+344 sh	$42.16	+$14.5K	770
2018-10-11	MyoKardia, Inc.M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	+2,500 sh	$11.95	+$29.9K	18,429
2018-10-11	MyoKardia, Inc.Stock Option (Right to Buy)M Exercise/Conversion	EVP, Chief Development Officer	MExercise/Conversion	−2,500 sh	—	—	101,341

Recent filings

Accepted (ET)
May 294
Lee June0001193125-26-249113
SEC(opens sec.gov)
Jan 164
Lee June0001193125-26-015485
SEC(opens sec.gov)
May 304
Lee June0000950170-25-079943
SEC(opens sec.gov)
Jan 134
Lee June0000950170-25-004915
SEC(opens sec.gov)
Oct 214
Lee June0000950170-24-116060
SEC(opens sec.gov)
Jun 124
Lee June0001209191-23-036510
SEC(opens sec.gov)
May 24
Lee June0001209191-23-026724
SEC(opens sec.gov)
Feb 244
Lee June0001209191-23-012893
SEC(opens sec.gov)
Feb 24
Lee June0001209191-23-006345
SEC(opens sec.gov)
Jun 134
Lee June0001209191-22-036531
SEC(opens sec.gov)
Feb 24
Lee June0001209191-22-006471
SEC(opens sec.gov)
Jan 104
Lee June0001209191-22-002684
SEC(opens sec.gov)
Nov 224
Lee June0001209191-21-066224
SEC(opens sec.gov)
Oct 294
Lee June0000899243-19-026147
SEC(opens sec.gov)

Companies

Address

C/O TENAYA THERAPEUTICS, INC. 171 OYSTER POINT BLVD., 5TH FLOOR

SOUTH SAN FRANCISCO, CA, 94080